Table 3A.
Registry survey: RAI patient and control cohort characteristics by center - young age groups.
| Study Center | Feasibility study sample, ARNICA | Registry, ARNICA | Institute of Endocrinology & Metabolism | National Tumor-Institute (INCA) | Dept. Nuclear Medicine, Institute of Oncology Vojvodina | Dept. Nuclear Medicine, University Hospital | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| City, country | Minsk, Belarus | Minsk, Belarus | Kiev, Ukraine | Rio de Janeiro, Brazil | Sremska Kamenica, Serbia | Coimbra, Portugal | ||||||
| N (% of combined study sample) | 202 (2.7%) | 1,328 (17.6%) | 1,297 (17.1%) | 89 (1.2%) | 32 (0.4%) | 15 (0.2%) | ||||||
| Cohorts | RAI patients | Controls* | RAI patients | Controls | RAI patients | Controls | RAI patients | Controls | RAI patients | Controls | RAI patients | Controls |
| n (% of RAI patient or control cohort) | 102 (1.6%) | 100 (9.0%) | 909 (14.1%) | 419 (37.5%) | 1,199 (18.6%) | 98 (8.8%) | 81 (1.3%) | 8 (0.7%) | 32 (10.5%) | 0 | 15 (0.2) | 0 |
| Current age (years, M ± SD) | 30.1 ± 1.9 | 34.3 ± 5.3 | 28.5 ± 5.2 | 36.7 ± 5.9 | 36.7 ± 5.9 | 25.6 ± 9.6 | 31.2 ± 8.9 | 29.3 ± 6.1 | 21.5 ± 5.1 | |||
| Age at first surgery (years, M ± SD) | 11.9 ± 3.2 | 17.6 ± 6.6 | 13.3 ± 3.3 | 23.6 ± 9.1 | 29.6 ± 8.1 | 26.2 ± 7.6 | 14.50 ± 3.0 | 14.5 ± 3.3 | 15.8 ± 3.9 | 14.2 ± 2.6 | ||
| <18 years, n (%) | 134 (32%) | 190 (15.8%) | 134 (32%) | 15 (100%) | ||||||||
| <40 years, n (%) | 416 (99.3%) | 1,125 (93.8%) | 416 (99.3%) | |||||||||
| Age at first RAI (years, M ± SD) | 12.8 ± 3.0 | 14.3 ± 3.4 | 14.5 ± 3.0 | 16.9 ± 0.81 | 15.5 ± 2.0 | |||||||
| <18 years, n (%) | 17 (53%) | 15 (100%) | ||||||||||
| <40 years, n (%) | 15 (47%) | |||||||||||
| Cumul. I-131 activity (GBq, M ± SD) | 11.8 ± 9.5 | 6.6 ± 3.8 | 10.4 ± 5.5 | 10.9 ± 0.2 | 7.2 ± 8.0 | |||||||
| Follow-up duration (years, M ± SD) | 17.3 ± 3.2 | 15.9 ± 3.4 | 17.4 ± 2.8 | 13.6 ± 6.2 | 11.1 ± 8.4 | 16.2 ± 8.2 | 13.1 ± 7.4 | 5.4 ± 4.5 | ||||
| SPM before DTC | ||||||||||||
| Breast cancer, n (%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Other cancers, n (%) | 0 | 0 | 8 (0.9%) | 5 (1.2%) | 0 | 0 | ||||||
| SPM after DTC/RAI | ||||||||||||
| Breast cancer, n (%) | 1 (0.9%) | 0 | 0 | 0 | 0 | 0 | ||||||
| Other cancers, n (%) | 3 (0.3%) | 1 (0.2%) | 0 | 0 | ||||||||
Cumul., cumulative; Dept., department; DTC, differentiated thyroid carcinoma; follic., I = 131, iodine-131; M ± SD, mean + standard deviation; RAI, radioiodine therapy; SPM, second primary malignancy.
*
Controls were patients with DTC who had not received RAI.